Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Platinum Resistant Epithelial Ovarian Carcinoma”

155 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 155 results

Early research (Phase 1)Looking for participantsNCT05950464
What this trial is testing

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Who this might be right for
Recurrent Endometrial CarcinomaRecurrent Endometrial Clear Cell AdenocarcinomaRecurrent Endometrial Endometrioid Adenocarcinoma+6 more
National Cancer Institute (NCI) 65
Early research (Phase 1)Active Not RecruitingNCT04092270
What this trial is testing

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Who this might be right for
Endometrial High Grade Endometrioid AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+26 more
National Cancer Institute (NCI) 55
Testing effectiveness (Phase 2)Study completedNCT04753216
What this trial is testing

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
Northwestern University 3
Large-scale testing (Phase 3)Study completedNCT04908787
What this trial is testing

A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

Who this might be right for
Ovarian Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd. 421
Testing effectiveness (Phase 2)UnknownNCT04846842
What this trial is testing

Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Who this might be right for
Epithelial Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Lee's Pharmaceutical Limited 46
Testing effectiveness (Phase 2)Study completedNCT00097019
What this trial is testing

Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed

Who this might be right for
Ovarian Cancer
Genentech, Inc. 53
Large-scale testing (Phase 3)UnknownNCT04055038
What this trial is testing

Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)

Who this might be right for
Ovarian CancerOvarian NeoplasmsSerous Adenocarcinoma+3 more
Blokhin's Russian Cancer Research Center 164
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06724263
What this trial is testing

A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors

Who this might be right for
Recurrent Platinum-resistant Epithelial Ovarian CancerTriple Negative Breast Cancer (TNBC)Cervical Cancers+4 more
Tasly Biopharmaceuticals Co., Ltd. 120
Testing effectiveness (Phase 2)Looking for participantsNCT05231122
What this trial is testing

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Who this might be right for
Ovarian Clear Cell AdenocarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Endometrial Serous Adenocarcinoma+12 more
Roswell Park Cancer Institute 80
Testing effectiveness (Phase 2)Ended earlyNCT02923739
What this trial is testing

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+17 more
M.D. Anderson Cancer Center 9
Early research (Phase 1)Ended earlyNCT05274451
What this trial is testing

Investigate LYL797 in Adults With Solid Tumors

Who this might be right for
Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerNon-small Cell Lung Cancer+20 more
Lyell Immunopharma, Inc. 57
Large-scale testing (Phase 3)UnknownNCT03220932
What this trial is testing

Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer

Who this might be right for
Ovarian Epithelial Cancer
Hospices Civils de Lyon 132
Early research (Phase 1)Study completedNCT03508570
What this trial is testing

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Who this might be right for
Malignant Peritoneal NeoplasmMalignant Retroperitoneal NeoplasmMetastatic Cervical Carcinoma+31 more
M.D. Anderson Cancer Center 26
Not applicableEnded earlyNCT03412630
What this trial is testing

Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
ECOG-ACRIN Cancer Research Group 1
Testing effectiveness (Phase 2)Study completedNCT03318900
What this trial is testing

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

Who this might be right for
COL6A3 PositiveHLA-A*0201 Positive Cells PresentPRAME Positive+1 more
M.D. Anderson Cancer Center 5
Large-scale testing (Phase 3)Ended earlyNCT01281254
What this trial is testing

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
Amgen 223
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Not applicableUnknownNCT01372787
What this trial is testing

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Who this might be right for
AnxietyFatigueNausea and Vomiting+20 more
Gynecologic Oncology Group 103
Testing effectiveness (Phase 2)Study completedNCT00005836
What this trial is testing

Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Testing effectiveness (Phase 2)Study completedNCT03029598
What this trial is testing

Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
University of Washington 29
Next Page